1.An Imported Case of Severe Falciparum Malaria with Prolonged Hemolytic Anemia Clinically Mimicking a Coinfection with Babesiosis.
Young Ju NA ; Jong Yil CHAI ; Bong Kwang JUNG ; Hyun Jung LEE ; Ji Young SONG ; Ji Hye JE ; Ji Hye SEO ; Sung Hun PARK ; Ji Seon CHOI ; Min Ja KIM
The Korean Journal of Parasitology 2014;52(6):667-672
While imported falciparum malaria has been increasingly reported in recent years in Korea, clinicians have difficulties in making a clinical diagnosis as well as in having accessibility to effective anti-malarial agents. Here we describe an unusual case of imported falciparum malaria with severe hemolytic anemia lasting over 2 weeks, clinically mimicking a coinfection with babesiosis. A 48-year old Korean man was diagnosed with severe falciparum malaria in France after traveling to the Republic of Benin, West Africa. He received a 1-day course of intravenous artesunate and a 7-day course of Malarone (atovaquone/proguanil) with supportive hemodialysis. Coming back to Korea 5 days after discharge, he was readmitted due to recurrent fever, and further treated with Malarone for 3 days. Both the peripheral blood smears and PCR test were positive for Plasmodium falciparum. However, he had prolonged severe hemolytic anemia (Hb 5.6 g/dl). Therefore, 10 days after the hospitalization, Babesia was considered to be potentially coinfected. A 7-day course of Malarone and azithromycin was empirically started. He became afebrile within 3 days of this babesiosis treatment, and hemolytic anemia profiles began to improve at the completion of the treatment. He has remained stable since his discharge. Unexpectedly, the PCR assays failed to detect DNA of Babesia spp. from blood. In addition, during the retrospective review of the case, the artesunate-induced delayed hemolytic anemia was considered as an alternative cause of the unexplained hemolytic anemia.
Anemia, Hemolytic/chemically induced/*etiology/*pathology
;
Anti-Bacterial Agents/therapeutic use
;
Antimalarials/therapeutic use
;
Artemisinins/adverse effects/therapeutic use
;
Atovaquone/therapeutic use
;
Azithromycin/therapeutic use
;
Babesiosis/complications/*diagnosis/drug therapy/*pathology
;
Benin
;
Blood/parasitology
;
Coinfection/diagnosis/pathology
;
Drug Combinations
;
France
;
Humans
;
Korea
;
Malaria, Falciparum/complications/*diagnosis/drug therapy/*pathology
;
Male
;
Middle Aged
;
Plasmodium falciparum/*isolation & purification
;
Proguanil/therapeutic use
;
Travel
;
Treatment Outcome
2.Coinfection of hepatitis A virus genotype IA and IIIA complicated with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive immunoglobulin M anti-hepatitis E virus: a case report.
Hee Sup KIM ; Sook Hyang JEONG ; Je Hyuck JANG ; Hyung Joon MYUNG ; Jin Wook KIM ; Soo Mee BANG ; Sang Hoon SONG ; Haeryoung KIM ; Hae Sun YUN
The Korean Journal of Hepatology 2011;17(4):323-327
A 37-year-old male presented with fever and jaundice was diagnosed as hepatitis A complicated with progressive cholestasis and severe autoimmune hemolytic anemia. He was treated with high-dose prednisolone (1.5 mg/kg), and eventually recovered. His initial serum contained genotype IA hepatitis A virus (HAV), which was subsequently replaced by genotype IIIA HAV. Moreover, at the time of development of hemolytic anemia, he became positive for immunoglobulin M (IgM) anti-hepatitis E virus (HEV). We detected HAV antigens in the liver biopsy specimen, while we detected neither HEV antigen in the liver nor HEV RNA in his serum. This is the first report of hepatitis A coinfected with two different genotypes manifesting with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive IgM anti-HEV.
Adult
;
Anemia, Hemolytic, Autoimmune/*diagnosis/drug therapy/etiology
;
Anti-Inflammatory Agents/therapeutic use
;
Cholestasis/*diagnosis/drug therapy/pathology
;
Coinfection/*diagnosis
;
Genotype
;
Hepatitis A/complications/*diagnosis/genetics
;
Hepatitis E/complications/*diagnosis/genetics
;
Humans
;
Immunoglobulin M/blood
;
Liver/pathology/virology
;
Male
;
Prednisolone/therapeutic use
;
RNA, Viral/blood
3.Predictors of Mortality in Korean Patients with Pyogenic Liver Abscess: A Single Center, Retrospective Study.
Se Hoon SOHN ; Kook Hyun KIM ; Jae Hyun PARK ; Tae Nyeun KIM
The Korean Journal of Gastroenterology 2016;67(5):238-244
BACKGROUND/AIMS: The mortality rate of pyogenic liver abscess (PLA) has decreased dramatically, but it remains a potentially life threatening disease. Most cases are cryptogenic or occur in elderly men with underlying biliary tract disease. Although several studies have addressed the characteristics and etiology of PLA, research on factors affecting PLA-associated mortality is lacking. This study intended to identify the clinical and radiological features, pathogens, complications, and predictors of mortality in Korean PLA patients. METHODS: The medical records of 231 PLA patients diagnosed at Yeungnam University Medical Center between January 2010 and January 2014 were analyzed. A diagnosis of PLA was made based on imaging studies and blood and abscess cultures. The clinical, radiological, and laboratory findings of patients were analyzed. RESULTS: The mean patient age was 64.0±12.9 years and the male to female ratio was 1.5:1. Klebsiella pneumoniae was the predominant organism isolated from hepatic abscesses (69.9%) and blood (74.2%). The most common complication was pleural effusion (35.8%) and most common co-infection was cholangitis (8.2%). The overall mortality rate of PLA was 6.9% (16/231), and was significantly higher in patients with a history of liver abscess (OR 5.970, 95% CI 1.207-29.529; p=0.028), bilirubinemia (>2 mg/dL) (OR 9.541, 95% CI 2.382-38.216; p=0.001), thrombocytopenia (<140×10(3)/µL) (OR 4.396, 95% CI 1.130-17.106; p=0.033), or anemia (<12 g/dL) (OR 13.277, 95% CI 1.476-119.423; p=0.021). CONCLUSIONS: The prognosis of PLA appears to be dependent on underlying pathologies and severity of condition. More aggressive treatment should be considered if a poor prognosis is expected.
Abscess
;
Academic Medical Centers
;
Aged
;
Anemia
;
Biliary Tract Diseases
;
Cholangitis
;
Coinfection
;
Diagnosis
;
Female
;
Humans
;
Hyperbilirubinemia
;
Klebsiella pneumoniae
;
Liver Abscess
;
Liver Abscess, Pyogenic*
;
Male
;
Medical Records
;
Mortality*
;
Pathology
;
Pleural Effusion
;
Prognosis
;
Retrospective Studies*
;
Risk Factors
;
Thrombocytopenia
4.Diagnosis and treatment of pulmonary tuberculosis.
Journal of the Korean Medical Association 2014;57(1):19-26
Pulmonary tuberculosis is still serious, one of the great public health problems in Korea. Recently, the increase in the aged population, human immunodeficiency virus coinfection, and drug-resistant tuberculosis have reinforced the need for improved rapid diagnostics and better treatment strategies. The basic principles of care for persons with, or suspected of having, pulmonary tuberculosis are the same worldwide. The standard guidelines and recent advances in diagnosis and treatment are summarized in this article. Prompt, accurate diagnosis of pulmonary tuberculosis should be established using chest radiography, sputum microscopy, and culture in liquid and solid medium. The further evaluation of chest imaging, histopathological examination of biopsy samples, nucleic acid amplification tests, immunological evaluation, and new molecular diagnostic tests supplement earlier, improved diagnosis, especially in patients with smear-negative pulmonary tuberculosis. Standardized treatment regimens of proven efficacy should be used with appropriate patient education and treatment support. The response to treatment and the presence of side effects of antituberculosis drugs should be monitored regularly. In addition, essential public health responsibilities and public-private collaboration must be carried out for effective patient care and pulmonary tuberculosis control.
Biopsy
;
Coinfection
;
Cooperative Behavior
;
Diagnosis*
;
HIV
;
Humans
;
Korea
;
Microscopy
;
Nucleic Acid Amplification Techniques
;
Pathology, Molecular
;
Patient Care
;
Patient Education as Topic
;
Public Health
;
Radiography
;
Sputum
;
Thorax
;
Tuberculosis
;
Tuberculosis, Multidrug-Resistant
;
Tuberculosis, Pulmonary*
5.Pulmonary coinfection by Pneumocystis jiroveci and Cryptococcus neoformans.
Bava JAVIER ; Lloveras SUSANA ; Garro SANTIAGO ; Troncoso ALCIDES
Asian Pacific Journal of Tropical Biomedicine 2012;2(1):80-82
We communicate the diagnosis by microscopy of a pulmonary coinfection produced by Cryptococcus neoformans and Pneumocystis jiroveci, from a respiratory secretion obtained by bronchoalveolar lavage of an AIDS patient. Our review of literature identified this coinfection as unusual presentation. Opportunistic infections associated with HIV infection are increasingly recognized. It may occur at an early stage of HIV-infection. Whereas concurrent opportunistic infections may occur, coexisting Pneumocystis jiroveci pneumonia (PCP) and disseminated cryptococcosis with cryptococcal pneumonia is uncommon. The lungs of individuals infected with HIV are often affected by opportunistic infections and tumours and over two-thirds of patients have at least one respiratory episode during the course of their disease. Pneumonia is the leading HIV-associated infection. We present the case of a man who presented dual Pneumocystis jiroveci and cryptococcal pneumonia in a patient with HIV. Definitive diagnosis of PCP and Cryptococcus requires demonstration of these organisms in pulmonary tissues or fluid. In patients with < 200/microliter CD4-lymphocytes, a bronchoalveolar lavage should be performed. This patient was successfully treated with amphotericin B and trimethoprim sulfamethoxazole. After 1 week the patient showed clinical and radiologic improvement and was discharged 3 weeks later.
Acquired Immunodeficiency Syndrome
;
complications
;
Adult
;
Amphotericin B
;
therapeutic use
;
Antifungal Agents
;
therapeutic use
;
Bronchoalveolar Lavage Fluid
;
microbiology
;
Coinfection
;
diagnosis
;
pathology
;
Cryptococcosis
;
complications
;
diagnosis
;
pathology
;
Cryptococcus neoformans
;
isolation & purification
;
Humans
;
Male
;
Microscopy
;
Pneumocystis carinii
;
isolation & purification
;
Pneumonia, Pneumocystis
;
complications
;
diagnosis
;
pathology
;
Treatment Outcome
;
Trimethoprim, Sulfamethoxazole Drug Combination
;
therapeutic use
6.Clinical features and treatment of refractory Mycoplasma pneumoniae pneumonia unresponded to conventional dose methylprednisolone in children.
Lili CHEN ; Jinrong LIU ; Shunying ZHAO ; Yungang YANG ; Jinzhun WU
Chinese Journal of Pediatrics 2014;52(3):172-176
OBJECTIVETo analyze the clinical manifestations of refractory Mycoplasma pneumoniae pneumonia (RMPP) which unresponded to methylprednisolone in the dosage of 2 mg/(kg·d) for 3 days.
METHODRetrospective analysis was performed on the clinical data of 110 children (64 boys and 46 girls) with RMPP. The patients were divided into "effective group" and "ineffective group" according to initial effect of 2 mg/(kg·d) methylprednisolone. The clinical manifestations, laboratory examination, radiological features and bronchofibroscopic findings of the children were compared. In order to seek the reference indexes which indicate nonresponsive to 2 mg/(kg·d) methylprednisolone, an ROC curve was made, of which the diagnostic cut-off was five independent correlation factors while grouping was made according to patients' different response to glucocorticosteroid.
RESULTThe effective group had 86 (86/110, 78.2%) children while ineffective group had 24 (24/110, 21.8%). The ineffective group children had the following performance: 16 children (16/24, 66.7%) in ineffective group had ultrahyperpyrexia (T ≥ 40 °C), which was significantly more severe compared to those in effective group (32/86, 37.3%, P < 0.01); the levels of white blood cell (WBC) count, percentage of neutrophils count (N), C-reactive protein (CRP), serum ferritin (SF), alanine transaminase (ALT), lactic dehydrogenase (LDH), creatine kinase isoenzyme (CK-MB) and fibrinogen (Fib) in ineffective group were significantly higher than those in effective group(P < 0.01); while percentage of lymphocyte count (L) was lower than that in effective group(P < 0.01). Proportion of mixed infection in ineffective group was higher than that in effective group (33.3% vs. 4.7%). Radiological manifestations: It was more frequently seen in ineffective group that chest CT scan indicated high density consolidation in no less than a whole pulmonary lobe and pulmonary necrosis (41.7% vs. 0%). Abundant secretions blockage (45.0% vs. 16.9%) and mucosal necrosis (37.5% vs. 8.1%) on bronchofibroscopy were more frequently seen in ineffective group. The critical values of the five independent correlation factors were CRP 110 mg/L, SF 328 mg/L, LDH 478 IU/L, N 0.78, L 0.13.
CONCLUSIONTreatment with 2 mg/(kg·d) methylprednisolone can improve clinical symptoms and radiological manifestations of most children with RMPP quickly, but it may be ineffective in some situations such as lasting high fever or ultrahyperpyrexia for more than 7 days, CRP ≥ 110 mg/L, N ≥ 0.78, L ≤ 0.13, serum LDH ≥ 478 IU/L, SF ≥ 328 µg/L, chest CT scan indicating high density consolidation in more than a whole pulmonary lobe involved and moderate-abundant pleural effusion.
Adrenal Cortex Hormones ; administration & dosage ; therapeutic use ; Anti-Bacterial Agents ; administration & dosage ; therapeutic use ; Bacterial Infections ; drug therapy ; epidemiology ; C-Reactive Protein ; analysis ; Child ; Child, Preschool ; Coinfection ; Female ; Ferritins ; blood ; Fever ; diagnosis ; drug therapy ; Humans ; Infusions, Intravenous ; Leukocyte Count ; Lung ; diagnostic imaging ; pathology ; Male ; Methylprednisolone ; administration & dosage ; therapeutic use ; Mycoplasma pneumoniae ; Pneumonia, Mycoplasma ; blood ; diagnosis ; drug therapy ; Radiography, Thoracic ; Retrospective Studies ; Tomography, X-Ray Computed ; Treatment Outcome